Sbir topic 307 phase i novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201100119C
- Awardee
-
Cellsight Technologies, Inc. UEI E3UQXACGFR43
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $247,568
Award facts
- Contract value 100% obligated
- $247,568.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 16 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Menlo Park, CA 94028, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $247,568 |
About this award
This is a $247,568 Firm Fixed Price contract awarded by the National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business. The contract is for research and development related to a novel PET imaging agent, [18F]F-ARAG, to assess response to cancer immunotherapies. This contract is part of NCI's Small Business Innovation Research (SBIR) program, which sets aside certain research and development contracts for small businesses. Cellsight Technologies has also received a $2 million Phase II SBIR contract from NCI to further develop the [18F]F-ARAG imaging agent, as well as a $300,000 Phase I SBIR contract to initially evaluate the agent for predicting response to cancer immunotherapies. Additionally, Cellsight is providing support services related to using the [18F]F-ARAG imaging biomarker to the University of California, San Francisco through grant subawards to assess the tracer for detecting heart damage associated with cancer treatments.
Quick answers
Who was awarded contract HHSN261201100119C?
HHSN261201100119C was awarded to Cellsight Technologies, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2011.
How much is contract HHSN261201100119C worth?
The government has obligated $247,568 on HHSN261201100119C.
Was contract HHSN261201100119C competed?
The extent of competition for HHSN261201100119C was full and open competition after exclusion of sources. The government received 16 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award